1, 2026, and will remove the new-to-market block on 1 According to the company, the move builds on the pharmacy benefit managers (PBMs) ongoing efforts to expand GLP-1 access for members while managing costs across the class
Gastrointestinal conditions may show earlier improvement, often becoming apparent during the first month of treatment
In addition to the efficacy of GLP-1 for the treatment of diabetes mellitus and obesity, preliminary evidence indicates GLP-1s have neuroprotective, therapeutic, and disease modification effects for select neurodegenerative disorders (e.g
The Science of Flexible Dieting and Its Impact on Weight Loss
Among these PTs, the most frequent SOCs were metabolism and nutrition disorders, hepatobiliary disorders and gastrointestinal disorders including AE signals of pancreatitis, impaired gastric emptying, cholelithiasis and dehydration with an occurrence quantity exceeding 100 ( Table S7 )
Together, they may support a more complete approach to skin health